The FDA has approved GlaxoSmithKline and Valeant Pharmaceuticals' new anti-epilepsy drug ezogabine (Potiga) as an add-on treatment for patients 18 and older with partial-onset seizures. But the FDA
committee overseeing approval also has concerns about the drug because 5% of patients experienced urinary dysfunction and retention. It will not be marketed until the Federal Drug Enforcement
Administration determines the final classification for the drug. The drugmakers expect it to be available by the end of the year.
Read the whole story at MedPageToday.com »